{"groups":[{"description":"Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1, 8, and 15 for the first course and on days 1 and 15 for all subsequent courses. Patients also receive low-dose oral cyclophosphamide 50 mg/d on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nbevacizumab: Given IV\n\ncyclophosphamide: Given PO","id":"FG000","title":"Treatment (Bevacizumab, Cyclophosphamide)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"70"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"70"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}